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LIFESTYLE FACTORS AFFECTING THE OCCURRENCE, PRESENTATION, 





Colorectal cancer is one of the most commonly diagnosed cancers in the 
United States with men and women facing a lifetime risk of between 5 and 6 
percent. Colorectal cancers develop from polyps which can be conventional 
adenomas or serrated polyps. Serrated polyps account for close to 25% of 
sporadic colorectal cancer. This study evaluated the available literature that 
considered lifestyle factors which have an established association with colorectal 
cancer. Tobacco smoking and a high consumption of alcohol were consistently 
associated with more adverse outcomes. A body mass index above 30 was also 
associated with less positive outcomes for patients. On the other hand, fish oil 
and a high level of pre-diagnosis physical activity were associated with 
improved outcomes among colorectal cancer patients. A diet of increased folate 
intake also resulted in reduced risk of colorectal cancer and was considered a 
protective factor. The results of this review can inform directions for future 
research on lifestyle factors associated with colorectal cancer and their use to 
improve the outcomes of colorectal cancer patients.  
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Colorectal cancer is the third most commonly diagnosed cancer in the 
United States, with similar incidence rates for both men and women (Siegel et al., 
2017). In the general United States population, the lifetime risk of colorectal 
cancer is between 5 and 6 percent, and the risk increases in those who have two 
or more family members with colorectal cancer (Lynch & de la Chapelle, 2003). 
From the North American Association of Central Cancer Registries, the incidence 
rates for colorectal cancer were highest in Alaska Natives and blacks and lowest 
in Asian/Pacific Islanders (Siegel et al., 2017).  
The highest rates of colorectal cancer are observed in industrialized 
countries. Countries that are undergoing transformations and adopting a more 
Western lifestyle have been observed to have an increased number of new cases. 
This has led to the conclusion that there are risk factors attributed to a more 
Western style of living, such as obesity and tobacco use, which result in an 
increased incidence of colorectal cancer when a community experiences a 
lifestyle transition. On the other hand, countries with higher consumption of 
fiber sources and less meat are observed to have a lower incidence of colorectal 
cancer (Durko & Malecka-Panas, 2014). 
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OBJECTIVES OF STUDY 
 
The reason for this study is to examine how various lifestyle factors affect 
the occurrence, presentation, and mortality rates of colorectal cancer. 
The specific objectives of this study are: 
1. To review the available literature on lifestyle factors and the observed 
impact these factors have on outcomes associated with colorectal 
cancer. 
2. To determine how strong the associations are between the evaluated 
lifestyle factors and the colorectal cancer outcomes. 
The results of this literature review may suggest that various lifestyle 
factors can be protective factors or risk factors for the occurrence, presentation, 




OVERVIEW OF COLORECTAL CANCER 
 
Colorectal cancer can develop from precursor polyps of which there are 
two types—conventional adenomas and serrated polyps (Kalimuthu et al., 2016). 
 
Conventional Adenomas 
Conventional adenomas (CA) are the precursors of up to 70% of colorectal 
cancers (Crockett & Nagtegaal, 2019). They are histologically defined by the 
proportion of tubular and villous components and can be classified as tubular, 
tubulovillous, or villous adenomas (Y. Kim et al., 2019) . Tubular adenomas have 
simple crypt-like glands and less than 25% villous component, whereas villous 
adenomas contain more than 75% villous component. Tubulovillous adenomas 
have between 25 and 75% villous component (Fleming et al., 2012).  
 
Adenoma Carcinoma Sequence 
Conventional adenomas develop by means of the adenoma-carcinoma 
sequence. This sequence involves the transformation of normal epithelium to 
dysplastic epithelium and then to carcinoma by gaining various genetic 




APC Gene  
One common mutation, known to affect the early parts of the adenoma-
carcinoma sequence, impacts the adenomatous polyposis coli (APC) tumor 
suppressor gene found on chromosome 5q21. Mutations of this gene in particular 
can result in familial adenomatous polyposis, which can eventually lead to the 
development of colorectal adenoma in middle-aged adults. The protein product 
of the APC gene is important and regulates other proteins, including beta-
catenin. In tumors with APC and beta-catenin mutations, there is increased beta-
catenin-transcription factor (TCF)-mediated transcription and increased 
transcription activity. Wild-type APC protein also promotes the stabilization of 
microtubules (Leslie et al., 2002). 
 
KRAS Gene 
Another mutation occurring early in the adenoma-carcinoma sequence is 
a mutation of the Kirsten rat sarcoma (KRAS) oncogene that is normally involved 
in proliferation and differentiation. Activating KRAS mutations are present in 
35%-42% of all colorectal carcinomas. The presence of mutant KRAS may be a 





Tumor protein p53 is the most commonly altered gene in human cancers. 
It has the ability to block cell proliferation in the presence of DNA damage and to 
stimulate DNA repair. If repair is insufficient, p53 promotes apoptosis. When p53 
is inactivated, the mutant becomes resistant to proteolysis and accumulates in the 
cell. Mutations of p53 have been observed in 50%-75% of adenocarcinomas 
(Leslie et al., 2002). 
 
DNA Methylation 
DNA hypermethylation of the promoter region of tumor suppressor genes 
is associated with transcriptional silencing. Hypermethylation of the APC gene is 
observed in 18% of sporadic carcinomas and sporadic adenomas. This process of 
hypermethylation that alters APC function is considered a required early event 
for tumorigenesis to occur. Another important case of hypermethylation is the 
human mutL homolog 1 (hMLH1) gene, which is hypermethylated in a majority 






Serrated polyps are responsible for almost 25% of sporadic colorectal 
cancers (Crockett & Nagtegaal, 2019). Serrated polyps are classified into three 
categories: traditional serrated adenomas, sessile serrated adenomas, and 
hyperplastic polyps. This latter category of hyperplastic polyps accounts for 75% 
of all serrated polyps (Crockett & Nagtegaal, 2019). Hyperplastic polyps have not 
been observed to exhibit dysplasia and are generally regarded to be 
nonmalignant (He et al., 2018).  
Sessile serrated adenomas and traditional serrated adenomas are 
considered precursors for colorectal cancers, whereas hyperplastic polyps are 
considered benign. Traditional serrated adenomas (TSAs) are rare, making up 
less than 2% of all colorectal polyps. They also account for only 5% of all serrated 
colorectal polyps (Pai et al., 2015). TSAs are molecularly heterogeneous and are 
more likely found in the distal part of the colorectum (Crockett & Nagtegaal, 
2019; Pai et al., 2015). 
Colorectal cancers have been identified as developing through three 
molecular pathways. These pathways are the serrated pathway, the mismatch 
repair pathway, and the conventional adenoma-carcinoma sequence. Colorectal 
cancers that arise from villous, tubular, or tubulovillous adenomas are thought to 
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do so by using the conventional adenoma-carcinoma sequence (Kalimuthu et al., 
2016). The adenoma-carcinoma pathway is responsible for approximately three-
fourths of total colorectal cancers (He et al., 2018). 
 
The Serrated Pathway  
Colorectal cancers that develop from serrated adenomas are thought to do 
so by means of the serrated pathway (Kalimuthu et al., 2016). The serrated 
pathway most likely involves mutations in both reticular activating system (RAS) 
and rapidly accelerated fibrosarcoma (RAF) genes, as well as methylation of 
cytosine-phosphate-guanine (CpG) islands, which is particularly seen in TSAs 
with a BRAF mutation (Crockett & Nagtegaal, 2019). 
Mutations in parts of the mitogen-activated protein kinase pathway, such 
as KRAS or BRAF, are the first step in the serrated pathway (Crockett & 
Nagtegaal, 2019). These mutations are most often in BRAF; for example, BRAF 
mutations accounted for nearly two-thirds of the observed polyps in a study of 
200 traditional sessile adenoma polyps (Bettington et al., 2015). This activating 
mutation leads to methylation of CpG islands, resulting in the CpG island 
methylator phenotype (CIMP). Methylation silences many genes, including 
tumor suppressor genes. The methylation of cyclin-dependent kinase inhibitor 
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2A (CDKN2A), a gene responsible for making p16, is commonly observed in 
TSAs (Crockett & Nagtegaal, 2019). p16 is an important tumor suppressor gene 
and is also used as a biomarker for diagnosing cervical intraepithelial neoplasia. 
The loss of some p16 staining was observed in BRAF mutant polyps (Bettington 
& Chetty, 2015). The hypermethylation of the p16 promoter was shown to result 
in a worse prognosis for colorectal cancer (Kitamura et al., 2019).  
Serrated polyps can also exhibit microsatellite instability (MSI) (Burnett-
Hartman et al., 2013). However, in comparison with sessile serrated adenoma 
(SSA), the TSA retains microsatellite stability and stains for MLH1 (Pai et al., 
2015). The MLH1 gene is another protein that plays an important role in DNA 
repair, and the silencing of this gene by methylation leads to microsatellite 
instability. MLH1 is not necessary for serrated neoplasia. It was observed in 7% 
of the BRAF mutant TSAs but none of the KRAS mutant TSAs (Bettington et al., 
2015). 
Further development of the serrated polyp is due to activation of the 
WNT signaling pathway, a characteristic shared with the development of 
conventional adenomas. Mutations that truncate the APC gene, a regulator of 
beta catenin, are present in most conventional adenomas but are present in only 
36% of TSAs. In one-third of TSAs, normal regulation of the WNT signaling 
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pathway is disrupted as a result of changes in the R-spondin family that causes 
an overexpression of R-spondin and a downregulation of RNF43 (Crockett & 
Nagtegaal, 2019). Advanced TSAs show increased staining in the nucleus for 
beta-catenin compared with regular TSAs (Bettington et al., 2015) . 
When compared with KRAS mutations, BRAF mutant TSAs are more 
likely to occur in a proximal location (Bettington et al., 2015). Overall, BRAF 
mutant adenomas have high levels of CIMP and are more likely to be found in 
the right colon (Crockett & Nagtegaal, 2019). BRAF mutant polyps are generally 
flat in their structure (Bettington et al., 2015). BRAF mutations are often 
associated with a CIMP, particularly when the adenoma is located in the 
proximal location. Distal BRAF mutant is still more likely to be CIMP-positive 
than distal KRAS mutant TSAs. Despite the fact that BRAF and KRAS mutant 
TSAs are related, they can result in different subtypes of colorectal cancer (CRC) 
(Bettington et al., 2015). 
 
Demographic Characteristics and Risk Factors 
TSAs are observed equally in both genders and typically become a 
concern after the age of 60 years (Kalimuthu et al., 2016). In a research study by 
Bettington and colleagues (2015), the average age of the patients with traditional 
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serrated adenoma was 64 years, with an even split in the sexes of the patients. In 
women, the odds of developing serrated polyps was inversely related to the use 
of estrogen-only postmenopausal hormone therapy (odds ratio [OR] = 0.63) 
(Burnett-Hartman et al., 2013).  
For serrated polyps, smoking has been linked as a risk factor; for example, 
tobacco users had 2.5 times the risk of serrated polyps compared with 
nonsmokers (He et al., 2018). This association is stronger than the observation 
between tobacco use and conventional adenomas (OR = 1.56; 95% CI [0.99, 2.44]). 
An association has also been observed between obesity and serrated polyps. 
Individuals classified in the highest body mass category had 30% higher risk of 
serrated polyps compared with individuals of normal weight (Burnett-Hartman 
et al., 2013). The evidence for this latter association, however, is described as 
weak because the correlation has not been observed in other studies (Crockett & 
Nagtegaal, 2019). 
 
Morphological Characteristics of TSA 
Traditional serrated adenomas (TSAs) have more heterogeneity in their 
morphology than many other polyps, but some of these characteristics are 
helpful in defining them (Bettington et al., 2015). TSA polyps grow outward, 
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away from the epithelium, and have a villiform morphology. The villous 
structure gives the TSA a “pine-cone” appearance that is characteristic of this 
polyp (Hasegawa et al., 2011). TSAs have an average size of 15–16 mm and can 
be sessile or pendunculated depending on their location (Bettington et al., 2015; 
Chetty, 2016).  
Traditional serrated adenomas are more commonly seen in proximal 
locations. Their size range means that they are usually larger than sessile serrated 
adenomas (Crockett & Nagtegaal, 2019). TSAs have eosinophilic cells because of 
an eosinophilic cytoplasm and ectopic crypt foci. Ectopic crypt foci (ECF) are an 
unusual development of crypts that is due to a mutation in protein signaling 
which results in a loss of orientation (Kalimuthu et al., 2016). The ectopic crypts 
develop at a right angle to the axis of the crypts, having no connection to the 
muscularis mucosae, and contain cells that continue to proliferate. ECF, however, 
are not observed in every case of TSA and are found in lower numbers in other 
adenomas (Crockett & Nagtegaal, 2019).  
The presence of luminal serrations is another distinct characteristic for 
identifying the traditional serrated adenomas (Kalimuthu et al., 2016). Luminal 
serrations give a saw-toothed appearance in the upper levels of the crypt of the 
epithelium (Rex et al., 2012). The serration is in the form of narrow slits which 
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distinguish TSAs from other types of serrated polyps (Crockett & Nagtegaal, 
2019). The nuclei are pencillate and contain chromatin and small nucleoli in 
addition to goblet cells. In nearly 50% of cases, TSA appears to have a raised two-
tier appearance (Hasegawa et al., 2011). 
TSA can also be distinguished by the expression of Ki-67, a protein that 
indicates that cells are about to divide. Compared with SSAs, which have an 
irregular and variable expression of Ki-67, TSA Ki-67 expression is mostly 
observed in just the ectopic crypts (Torlakovic et al., 2008). The level of Ki-67 
staining observed in the ectopic crypts is not always high (Bettington & Chetty, 
2015). The presence of ectopic crypts with bases not attached to the muscularis 
mucosae is another characteristic that is used to identify TSA. This characteristic 




Traditional serrated adenomas are typically found in the distal colorectum 
where up to 71% of all TSA polyps occur (Bettington et al., 2015; Crockett & 
Nagtegaal, 2019). About 61.3% of these polyps are preferentially located in the 





Traditional serrated adenomas are not categorized as being intrinsically 
dysplastic, but they can undergo two different types of dysplasia. The less 
understood form of dysplasia is the serrated dysplasia, which is initiated by 
BRAF mutations and can be classified as either low grade or high grade. The 
low-grade serrated dysplasia exhibits less drastic changes, such as enlarged 
nuclei and low mitotic activity in dispersed chromatin, whereas the high-grade 
dysplasia is characterized by multiple atypical structures and functions 
(Kalimuthu et al., 2016). 
TSAs with high-grade dysplasia have higher levels of KRAS mutation and 
lower levels of BRAF mutation compared with those with low-grade dysplasia. 
TSAs with high-grade dysplasia also have higher levels of specific kinds of 
methylation (K. M. Kim et al., 2010). Nearly one-fourth of TSAs have 
adenomatous dysplasia (Chetty, 2016). 
 
Synchrous Neoplasia 
Traditional serrated adenomas (TSAs) are often found with other types of 
polyps, but they can be identified by their distinct characteristics as already 
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discussed. TSAs are most often detected with hyperplastic polyps (in some cases, 
up to 52% of the time), but they also occur with sessile serrated adenomas (SSA) 
and villous/tubulovillous adenomas (VA/TVAs)(Kalimuthu et al., 2016). In an 
analysis of sigmoidoscopy data, individuals with large serrated polyps had a 4 
times increase in long-term risk of colorectal cancer compared with those 
without polyps (Holme et al., 2015). Individuals with serrated polyps were also 
at risk for recurrent serrated polyps compared with individuals having other 
types of polyps (Macaron et al., 2015). In addition, a study of 727 Korean patients 
having serrated adenomas showed that patients with TSAs were more likely 
than those with conventional adenomas (CAs) to develop metachronous polyps 
(66.1% vs 43.5%, respectively) (Yoon et al., 2015). These metachronous polyps 
were mostly conventional adenomas. The group with TSAs also had a higher 
rate of developing a high-risk adenoma (HRA) compared with a matched group 
with CAs (about one-half of the TSA group vs about one-third of the CA group). 
When a multivariate analysis was carried out, the presence of a TSA resulted in 
an increased odds of having an HRA (OR 2.37) (Pai et al., 2015; Yoon et al., 2015). 
TSAs associated with an SSA lesion are usually seen in the proximal colon, 
whereas TSAs with a hyperplastic polyp or no precursor lesion are typically 





Smoking has been established in multiple studies to lead to colorectal 
cancers, with long-term heavy smokers having 2–3 times the risk of colorectal 
cancer (Tulinius et al., 1997). A stronger association between smoking and 
colorectal cancer was observed with serrated polyps and their pathway than 
with the adenoma-carcinoma sequence (He et al., 2018). 
In a meta-analysis conducted by Botteri and associates (2008) that 
evaluated 106 studies and 39,799 patients, it was estimated that individuals who 
had ever smoked were 18% more likely to develop colorectal cancer than those 
who had never smoked. This analysis also found a dose-response association for 
occurrence of colorectal cancer when pack-years and cigarettes a day were 
considered. Ever-smokers also had higher levels of mortality with a risk estimate 
of 1.25 (95% CI [1.14, 1.37]). Smoking resulted in an increased absolute risk of 6 
deaths for every 100,000 individuals in one year (95% CI [4.2, 7.6]) (Botteri et al., 
2008). 
Studies have also been conducted to observe if the increased risk of 
colorectal cancer that can be attributed to cigarette smoking had differing impact 
based on sex and anatomical site. A study by Gram and coworkers (2020) 
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considered nearly 5000 cases of colorectal cancer, and using regression models, 
they compared these cases to never-smokers of the same sex. In their analysis, 
they observed that male ever-smokers had a 39% higher risk of left or distal 
colon cancer compared with male never-smokers (HR = 1.39, 95% CI [1.16, 1.67]), 
with the hazard ratio (HR) for right colon cancer remaining comparable with 
nonsmokers (HR = 1.03, 95% CI [0.89, 1.18]). Female ever-smokers had a 20% 
higher risk of right or proximal colon cancer compared with female never-
smokers (HR = 1.20, 95% CI [1.06, 1.36]), with the hazard ratio for left colon 
cancer remaining at 0.96 (95% CI [0.80, 1.15]). Compared with male smokers, 
female smokers also had an overall increased risk of rectal cancer that was 
associated with pack-years (40% vs 58%). Men who smoked more than 20 pack-
years had a 61% higher risk of rectal cancer (HR = 1.61, 95% CI [1.29, 2.00]) than 
never-smokers, whereas for women, their risk was doubled (HR = 2.09, 95% CI 
[1.54, 2.83]) compared with never-smokers. A direct association between 
smoking variables such as duration of smoking, number of cigarettes a day, and 
number of pack-years was observed in proximal cancers for women and distal 
cancers for men (Gram et al., 2020). 
In an analysis of conventional adenoma and serrated polyps, smokers 
only slightly increased their risk of adenomas (RR = 1.29, 95% CI [1.11, 1.49]) but 
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greatly increased their risk of serrated polyps (RR = 2.01, 95% CI [1.66, 2.44]). 
Former smokers had an increased adenoma risk of 1.18 (95% CI [1.05, 1.32]) and 
increased serrated polyp risk of 1.42 (95% CI [1.20, 1.68]). For a combination of 
serrated polyps and adenomas, the risk estimate for the combination was similar 
to that of serrated polyps and was consistent even when stratified by sex 
(Figueiredo et al., 2015).  
In a study of 2915 individuals by Figueiredo and associates (2015), 
smoking intensity measured by number of cigarettes a day was not significantly 
associated with an increased risk, but duration of smoking was modestly 
associated with risk. Smoking cessation was associated with a decreased risk for 
those who had quit smoking 20 or more years ago when compared with current 
smokers (RR = 0.60, 95% CI [0.48, 0.75]). Former smokers also had a lower 
relative risk of having serrated lesions greater than 1 cm (RR = 1.62, 95% CI [1.27, 
2.07] vs RR = 1.21, 95% CI [0.98, 1.49]). In addition, a difference in risk was 
observed based on location, with an increased risk of 2.28 (95% CI [1.85, 2.80]) for 
serrated polyps in the left colorectum but no increased risk for serrated polyps 
on the right side (Figueiredo et al., 2015). 
In a meta-analysis of 43 studies conducted by Bailie et al. (2017), tobacco 
smoking was found to increase the risk of serrated polyps (RR = 2.47, 95% CI 
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[2.12, 2.87]). Twenty-six of the 43 studies investigated hyperplastic/serrated 
polyp risk with studies originating mostly in the United States. Five of the 
studies originated in Europe, and another five were focused on Asian 
populations. The results of this meta-analysis showed an increased risk for 
serrated polyps overall, but a stronger association was found with sessile 
serrated adenoma risk (RR = 3.40, 95% CI [1.90, 6.07]) compared with 
hyperplastic risk (RR = 2.34, 95% CI [2.00, 2.73])(Bailie et al., 2017).  
Cancers that are BRAF-mutated and high in microsatellite instability and 
CpG island methylation are more likely to be associated with cigarette smoking. 
CIMP-positive tumors were found to be significantly related to BRAF mutations 
(V600E), with an odds ratio of 39.52 (95% CI [11.44, 136.56]). CIMP-positive, 
unstable tumors were more likely to be located in the proximal region of the 
colorectum, whereas CIMP-positive, microsatellite-stable tumors were less likely 
to be found in the proximal region. Compared with CIMP-positive, 
microsatellite-stable tumors, CIMP-positive, unstable tumors were more likely to 
have the BRAF V600E mutation (64.1% vs 17.6%) (Samowitz et al., 2005).  
In a case control study of patients who had colon cancer between the ages 
of 30 and 79, information on lifestyle factors was collected using a questionnaire 
(Slattery, 2000). Patients who had tumors that tested positive for microsatellite 
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instability (MSI) were more likely to smoke 20 or more cigarettes a day than 
those who tested negative (for men, OR = 1.6, 95% CI [1.0, 2.5], and for women, 
OR = 2.2, 95% CI [1.4, 3.5]) (Slattery, 2000). For smokers who had smoked for 35 
or more years and for patients who had started to smoke at a young age, the 
association was strongest. A linear association between increased risk of MSI-
positive tumors and amount smoked was observed to be statistically significant 
(Figueiredo et al., 2015). Using the data collected in this study, the researchers 













In a longitudinal study of 555 patients with colorectal cancer, molecular 
marker data were obtained as summarized in Table 1 (Limsui et al., 2010). 
 
 
Table 1. Summary of Molecular Biomarker Data From the Iowa Women’s 




Number patients (% total ) 
High/Positive 
Number patients (% total) 
Microsatellite Instabilityb 393 (71%) 147 (26%) 
CIMPc  363 (65%) 164 (30%) 
BRAF Mutationd 385 (69%) 152 (27%) 
 
aThis table shows the characteristics of 555 women patients from the larger cohort study with 
incident colorectal cancer (diagnosed between January 1, 1986, and December 31, 2002) whose 
molecular marker data were collected. The women were characterized by the subtype 
distribution for these markers. Data taken from (Limsui et al., 2010). 
bMicrosatellite instability (MSI): Low microsatellite instability (MSI-low) indicates that the 
subtype is microsatellite stable, whereas high microsatellite instability (MSI-high) indicates that 
the subtype is microsatellite unstable 
cCIMP (CpG island methylator phenotype): CIMP-positive indicates a positive status for the CpG 
island methylator phenotype, whereas CIMP-negative indicates a negative status for the CpG 
island methylator phenotype. 
dBRAF mutation: BRAF mutant-positive indicates the presence of a BRAF mutation in the 
subtype, whereas BRAF mutant-negative indicates the absence of a BRAF mutant subtype. 
 
 
In addition, 143 (26%) of the patients in Table 1 had deficient DNA mismatch 
repair protein expression (including absence of MLH1, MSH6, or PMS2), 404 
(73%) of the patients had proficient DNA mismatch repair protein expression, 
and 130 (23%) of the patients had MLH1 promoter hypermethylation. Based on 
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the results in Table 1, a strong correlation was observed between the MSI-high, 
CIMP-positive, and BRAF mutant-positive expressions. Also, 96% of the patients 
who were MSI-high had a deficient DNA mismatch repair protein expression 
(Limsui et al., 2010). 
In age-adjusted risk models that accounted for potential confounders, 
Limsui and colleagues (2010) reported that ever-smokers had a higher overall 
colorectal cancer risk than those who had never smoked (RR = 1.19, 95% CI [1.05, 
1.35). When smoking variables (e.g., total duration of smoking, age at start, 
average number of cigarettes a day, pack-years, and induction period) were 
considered, a positive dose-response relationship was observed. Each smoking 
variable on its own was associated with increased risk for cancer in the proximal 
area of the colorectum. From these variables, having an average number of 
cigarettes greater than 20 a day or having cumulative pack-years of 40 or more 
had the highest risks associated with them for proximal colorectal cancer. 
Patients who smoked more than 20 cigarettes a day had a risk ratio (RR) of 1.71 
(95% CI [1.24, 2.36]), and those with more than 40 pack-years had a risk ratio of 
1.58 (95% CI [1.21, 2.08]). Smoking duration and the period from time of 
exposure to onset of the disease were associated with colorectal risk in the distal 
region (Limsui et al., 2010). 
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A study by Curtin and colleagues (2009) estimated that smokers who had 
a history of more than 20 pack-years had increased odds of specifically 
developing CIMP-positive (OR = 1.5, 95% CI [0.8, 2.8]) or BRAF mutant (OR = 4.2, 
95% CI [1.3, 14.2]) rectal cancers. 
In addition to evaluating the relationship between cigarette smoking and 
colorectal cancer, Limsui and colleagues (2010) evaluated risk estimates for 
various colorectal cancer subtypes which were MSI-high, CIMP-positive, or 
BRAF mutant-positive. Each of these subtypes showed a strong association with 
the smoking variables previously discussed. Patients who had ever smoked had 
increased risk for tumors that were MSI-high (RR = 1.66, 95% CI [1.16, 2.36]), 
CIMP-positive (RR = 1.46, 95% CI [1.04, 2.05]), or BRAF mutant-positive (RR = 
1.57, 95% CI [1.11, 2.23]) subtypes of colorectal cancer. In this study, cigarette 
smoking status was not associated with having tumors that were MSI-stable (RR 
= 1.00, 95% CI [0.79, 1.25]), CIMP-negative (RR = 1.02., 95% CI [0.81, 1.30]), or 
BRAF wild type (RR = 1.00, 95% CI [0.65, 1.27]). 
Among ever-smokers, current smokers had the highest risk for MSI-high 
tumors (RR = 1.99, 95% CI [1.26, 3.14]) when compared with former smokers. 
They had increased risk for CIMP-positive (RR = 1.88, 95% CI [1.22, 2.90]) and 
BRAF mutant (RR = 1.92, 95% CI [1.22, 3.02]) colorectal cancer subtypes. Former 
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smokers also had a higher risk than nonsmokers but a lower risk than current 
smokers for MSI-high (RR = 1.46, 95% CI [0.95, 2.23]), CIMP-positive (RR = 1.21, 
95% CI [0.79, 1.84]), and BRAF mutation-positive (RR = 1.36, 95% CI [0.89, 2.08]) 
colorectal cancer subtypes (Limsui et al., 2010).  
Limsui et al. (2010) concluded that although cigarette smoking is very 
strongly associated with MSI-high, CIMP-positive, and BRAF mutant-positive 
colorectal cancer subtypes, the association between cigarette smoking and overall 
colorectal cancer is not as strong.  
Samowitz and coworkers (2006) furthered this work by investigating 
whether the association between smoking and colorectal cancer was due to BRAF 
and CIMP mutations. They discovered that those who smoked more than 20 
cigarettes a day when compared with nonsmokers had an increased risk of 
CIMP-positive colon cancer (OR = 2.0, 95% CI [1.43, 2.97]). They also had an 
increased risk of BRAF V600E mutations (OR = 3.16, 95% CI [1.80, 5.54]). The 
association between cigarette smoking and increased colorectal cancer risk was 
only observed in tumors that were CIMP-positive or BRAF-mutated, regardless 
of the presence or absence of microsatellite instability. More BRAF mutations 
were observed in CIMP-positive tumors, with 95.4% of CIMP-positive tumors 
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having BRAF mutations compared with 7.9% of CIMP-negative tumors 
(Samowitz et al., 2006).  
Smoking more than 20 cigarettes a day was also associated with an 
increased risk of having CIMP-positive cancer than CIMP-negative cancer 
(Nishihara et al., 2013). Compared with never-smokers, those who smoked 40 or 
more pack-years had increased risk of CIMP-positive cancers (HR = 2.12, 95% CI 
[1.48, 3.03]), MSI-high cancers (HR = 2.27, 95% CI [1.56, 3.31]), and BRAF-
mutated cancers (HR = 2.0, 95% CI [1.37, 2.92 (Nishihara et al., 2013).  
Because of the strong association between CIMP-positive and MSI-high or 
BRAF mutations in the occurrence of colorectal cancer, Nishihara and colleagues 
(2013) conducted an analysis between pack-years and cancer risk using a 
combined molecular analysis of CIMP and MSI subtypes. They observed that 
compared with never-smokers, those who had 40 or more pack-years had a 
higher risk of CIMP-positive/MSI-high cancers (HR = 2.75, 95% CI [1.78, 4.26]). 
This association was not observed in other combined molecular subtypes for 
CIMP and MSI status. 
When a combined molecular analysis for CIMP/BRAF subtypes was 
conducted, pack-years was associated with a higher risk for CIMP-positive 
cancers. Pack-years was also significantly associated with an increased risk for 
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MSI-high cancers, regardless of BRAF status. This association was not seen in 
microsatellite-stable cancers (Nishihara et al., 2013). 
Samowitz and coworkers (2006) also investigated if there was an 
association between BRAF status and smoking. Their hypothesis was that the 
reason cigarette smoking was able to impact the risk of colorectal cancer was due 
to CIMP and BRAF mutations. They observed that regardless of microsatellite 
instability status, cigarette smoking was associated with colon cancer patients 
who had a BRAF V600E mutation. A dose-response relationship was reported for 
colon cancers overall as well as cancers by microsatellite instability status. 
Patients who smoked more than 20 cigarettes a day had a higher risk of having 
colon cancer with a BRAF V600E mutation when compared with nonsmokers 
(OR = 3.16, 95% CI [1.80, 5.54]). Smoking also increased the risk of colon cancers 
without BRAF mutations, although the increased risk was less than that observed 
in BRAF-mutated cancers (OR = 1.32 vs OR = 3.16). When cases were compared, 
cigarette smoking was more strongly associated with BRAF-mutated cancers 
than wild-type BRAF cancers. Smoking more than 20 cigarettes a day increased 
the risk of having a colon cancer that had a BRAF V600E mutation (OR = 2.46, 




Following the previous work, Samowitz et al. (2006) conducted further 
analysis on different combinations of CIMP and BRAF mutations to better 
understand the effects of smoking. Smoking was not associated with an 
increased risk in CIMP-negative colon cancers that had wild-type BRAF. In 
CIMP-positive colon cancers with wild-type BRAF, however, there was an 
increased risk for those smoking more than 20 cigarettes a day regardless of 
microsatellite instability status (OR =1.91, 95% CI [1.23, 2.97]). Cigarette smoking 
was also associated with CIMP-positive colon cancer with mutant BRAF (OR= 
2.85, 95% CI [1.53, 5.29]). Overall, cigarette smoking was associated with 
increased risk of CIMP-positive colon cancers that could be BRAF wild type or 
BRAF mutant. In addition, more methylated CpG islands were found in BRAF-
mutated tumors than in BRAF wild-type tumors, and 93% of all BRAF-mutated 
tumors that were analyzed in this study had a CIMP-positive status (Samowitz et 
al., 2006).  
In a cross-sectional study of 1321 asymptomatic adults, smoking was the 
only risk factor identified for hyperplastic polyps with smokers having an odds 
ratio of 1.98 (95% CI [1.41, 2.78]) (Hassan et al., 2010). An even larger study 
which analyzed participants in the Nurses’ Health Study and Health 
Professionals’ Follow-Up Study evaluated nearly 8000 participants who had 
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serrated polyps. In this study, current smokers who had a 30-pack-year history 
were observed to have 2.52 times the risk of serrated polyps compared with 
nonsmokers (95% CI [2.29, 2.78]). The 30-pack-year history mark was also used to 
identify individuals who were at a high risk for lung cancer (Crockett, 2019). 
For another cross-sectional study of 30,000 Korean participants 
undergoing colonoscopy, the group was separated into categories of younger 
and older patients. The younger patients (n = 13,618) were between the ages of 
30–49, whereas the older patients were 50 and older (n = 17,999). In both groups 
the current smokers had a higher risk of having sessile serrated lesions when 
compared with never-smokers. The younger group had lower odds of 1.53 (95% 
CI [1.00, 2.32]) when compared with the older group with an odds ratio of 3.98 
(95% CI [2.38, 6.65]). A dose-response gradient was also observed. Participants 
who had higher pack-years had an increased risk of sessile serrated lesions, and 
smokers overall were more likely to have larger or multiple lesions. When 
smoking was ceased for 5 or more years, the risk of sessile serrated lesions 
decreased (OR = 0.49, 95% CI [0.28, 0.86]), showing that behavior modification 
could still have an impact on the prevention of serrated polyps. A 20 or more 
pack-years history was more strongly associated with distal sessile serrated 
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lesions than with proximal lesions (OR = 2.71, 95% CI [1.27, 5.77] vs OR = 1.60, 
95% CI [1.00, 2.54]) (Ji Young Lee et al., 2019). 
As smoking variables were associated with colorectal cancer and CIMP-
positive tumors in particular, smoking cessation was also significantly associated 
with a decreased risk of CIMP-positive colorectal cancer (Nishihara et al., 2013). 
Compared with current smokers, hazard ratios for groups that had ceased 
smoking decreased with an increase in time since cessation. For 10–19 years of 
cessation, the hazard ratio was 0.53 (95% CI [0.29, 0.95]), for 20–39 years, 0.52 
(95% CI [0.32, 0.85]), and for greater than or equal to 40 years, 0.50 (95% CI [0.27, 
0.94]). This indicated that when compared with current smokers, former smokers 
with long-term cessation only had half the risk (Nishihara et al., 2013).  
In this study by Nishihara and colleagues (2013), the hazard ratio of 
former smokers who had a long-term history of cessation was more similar with 
the hazard ratio of never-smokers compared with current smokers (HR = 0.47, 
95% CI [0.31, 0.7]) than the hazard ratio of current smokers compared with 
never-smokers (HR = 2.08, 95% CI [1.35, 3.20]). This association was only 
observed in CIMP-positive colorectal cancers because CIMP-negative cancers 
were not significantly associated with smoking cessation (Nishihara et al., 2013). 
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A longer duration of smoking cessation was also associated with a 
decrease in MSI-high cancer risk but was not significantly associated with 
cancers that had microsatellite stability. Smoking cessation was therefore 
associated with MSI status and CIMP status, but it did not seem to significantly 
differ by BRAF mutation status (Nishihara et al., 2013). This relationship was 
explained by the strong association observed between CIMP-positive and MSI-
high colorectal cancers (Samowitz et al., 2006). In a combined analysis, however, 
the risk reduction associated with smoking cessation occurred in CIMP-positive 
cancers regardless of MSI status. The same result was observed in an analysis of 
BRAF and CIMP status, with a relationship existing between CIMP-positive 
cancers and smoking cessation regardless of BRAF mutation status (Samowitz et 
al., 2006). 
Nishihara et al. (2013) also evaluated the association between smoking 
cessation and pack-years. They concluded that among current or former smokers 
with 20 or more pack-years, longer periods of cessation were associated with a 
significantly lower risk of colorectal cancer.  
Compared with never-smokers, ever-smokers reported higher alcohol 
consumption. Furthermore, both body mass index and physical activity level 
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were lower among ever-smokers, whereas waist-to-hip ratio was similar for both 






Alcohol consumption has long been considered an important modifiable 
risk factor for cancers with a 2002 study attributing 5.1% of cancer deaths in men 
and 1.3% of cancer deaths in women to alcohol drinking (Boffetta et al., 2006). 
Alcohol intake has been linked to various cancers including cancer of the 
colorectum. A study in Germany showed increased levels of CRC mortality as a 
result of heavy drinking (HR = 1.37, 95% CI [1.06, 1.78]). Heavy drinking was 
classified as greater than 50 g/day for men and greater than 25 g/day for women 
(Walter et al., 2016). Another meta-analysis of 32,486 patients showed that heavy 
pre-diagnostic alcohol consumption was not significantly associated with 
colorectal cancer survival. However, the study found a nonlinear association 
between pre-diagnostic alcohol consumption and mortality of all causes. At <30 
g/day of alcohol consumption, a reduction in risk ratio was observed (Y. Kim et 
al., 2019). 
An analysis of various studies showed an increase in colorectal cancer risk 
for those with a consistently high alcohol intake when compared with 
nondrinkers. An elevated risk was observed for those who consumed 30 g/day or 
more. The relative risk for alcohol consumption of 30 g/day to less than 45 g/day 
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was 1.21 (95% CI [1.04, 1.42]), whereas drinkers who consumed 45 g/day or 
greater had a relative risk of 1.51 compared with nondrinkers. The association 
between alcohol consumption and colorectal cancer risk was consistent 
regardless of the site of the cancer (Cho et al., 2004). For a study that separated 
men and women with light/moderate consumption of alcohol, the results 
showed a decreased risk of CRC compared with none/occasional consumption, 
with women having slightly lower risk than men (OR = 0.88, 95% CI [0.82, 0.95] 
vs OR = 0.96, 95% CI [0.88, 1.05]). Very heavy alcohol consumption, however, 
was associated with an increased risk of colorectal cancer in men (OR = 1.32, 95% 
CI [1.15, 1.51]) (McNabb et al., 2020). 
The effect of alcohol on risk of colorectal cancer was modulated by other 
factors including family history, sex, and body mass index. For an alcohol 
consumption of ≥30 g/day, the risk ratio for colorectal cancer increased from 1.20 
to 2.80 when there was a family history of colorectal cancer (Rossi et al., 2018).  
In one study, the association between alcohol intake and colorectal cancer 
was more evident in individuals with a lower body mass and resulted in even 
more elevated risk for men. Women with a body mass index (BMI) less than 22 
and an alcohol intake of 30 g/day or greater had an increased risk of 1.60 (95% CI 
[1.07, 2.41]), whereas men in the same category had a risk of 3.51 (95% CI [1.45, 
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8.50]) (Cho et al., 2004). In another study focused on subjects who consumed an 
alcoholic beverage once a week for six months or longer, those who had a BMI 
lower than 30 had lower risk for colorectal cancer compared with those who had 
a BMI greater than 30 (OR = 0.8, 95% CI [0.60, 1.10] vs OR = 2.2 (95% CI [1.20, 
4.00]) (Zhao et al., 2012). 
A meta-analysis of 16 case-control studies observed that compared with 
none/occasional consumption, light/moderate alcohol consumption did not 
result in reduced risk among obese individuals (OR = 1.07, 95% CI [0.93, 1.22], p = 
0.366). Obesity on its own was linked to having an association with colorectal 
cancer (McNabb et al., 2020).  
In another study that featured a multiethnic cohort including black, 
Native Hawaiian, Japanese American, Latino, and white persons in Hawaii and 
California, an increased risk was observed among Native Hawaiians, Japanese 
Americans, Latinos, and white persons. An increased risk was also observed in 
those who had a BMI value <25. Beer and wine consumption was observed to 
have a positive association with colorectal cancer risk. Liquor consumption did 
not have the same association, and this association was stronger for rectum and 
left-colon tumors (Park et al., 2019). In another study, however, wine 
consumption was associated with a lower risk of mortality from all-causes and 
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colorectal cancer, but a positive association was observed between moderate 
liquor consumption and all-causes of mortality (Y. Kim et al., 2019). 
Some studies had also shown that alcohol consumption was the highest 
risk for cancers in the rectum, with one study concluding that for an average 
lifetime consumption of greater than 60 g/day, the hazard ratio in the rectum was 
2.59 (95% CI [1.62, 4.13]) compared with 2.22 (95% CI [1.20, 4.13]) in the distal 
colon and 1.22 (95% CI [0.59, 2.51]) in the proximal colon (Ferrari, 2007). Similar 
results were observed in a study in which the subjects consumed ≥30 g/day of 
alcohol, with an HR for rectosigmoid cancer of 2.07 (95% CI [1.03, 4.18]), distal 
colon cancer of 1.41 (95% CI [0.94, 2.11]), and proximal colon cancer of 1.29 (95% 
CI [0.85, 1.96]) (Bongaerts et al., 2008).  
Another meta-analysis, however, linked heavy alcohol consumption with 
an increased risk of distal colon cancer (OR = 1.19, 95% CI [1.01, 1.45], p = 0.004) 
but not proximal colon cancer (OR = 1.05, 95% CI [0.90, 1.23], p = 0.511). Stronger 
associations were also observed in this study between very heavy alcohol 
consumption and Stage 1 and Stage 4 cancers (McNabb et al., 2020). 
In a meta-analysis that compared the risk ratio of drinkers to nondrinkers, 
any drinkers had a risk ratio of 1.12; light drinkers, 1.00 (95% CI [0.95, 1.05]); 
moderate drinkers, 1.21 (95% CI [1.13, 1.28]); and heavy drinkers, 1.52 (95% CI 
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[1.27, 1.81]). Those who were classified as heavy drinkers had a higher relative 
risk for colon cancer than any other drinkers. Moderate and heavy drinkers had 
an increased risk for cancer of the distal colon compared with the proximal colon, 
but this result was not statistically significant (Fedirko et al., 2011).  
In another meta-analysis, the risk ratio was 1.07 (95% CI [1.02, 1.13]) for 
light drinkers (≤12.5 g/day), 1.23 (95% CI [1.15, 1.32]) for moderate drinkers (12.6 
to 49.9 g/day), and 1.37 (95% CI [1.26, 1.49]) for heavy drinkers (≥50 g/day). These 
results exhibited a similar trend to what was previously reported (Wang et al., 
2015).  
Alcohol has been linked to the formation of adenomatous polyps and 
serrated polyps. For serrated polyp formation, the relative risk was 1.30 (95% CI 
[1.15, 1.48]) when comparing high-volume drinkers with low-volume drinkers, 
and an odds ratio of 2.04 (95% CI [1.28, 3.26]) was observed in those who 
consumed seven or more drinks/week (Rossi et al., 2018). Among drinkers who 
consumed more than 50 g/day, 72% of cases who had a previous high-risk 
adenoma or cancer developed another compared with a 57% development rate 




Alcohol is thought to induce carcinogenesis through various molecular 
pathways including the release of acetaldehyde which is a metabolite of alcohol. 
Acetaldehyde reacts with DNA to form cancer-promoting compounds (Seitz & 
Becker, 2007). These metabolites can also cause lipid peroxidation, dysfunction of 
the epithelial layer, and disruption of the immune function (Rossi et al., 2018). 
Oxidative stress is another way that alcohol induces cancer development. In 
addition, abnormal DNA methylation patterns can interfere with normal 
pathways leading to cancer development. Studies have also shown that alcohol 
uses epigenetic processes to influence colorectal carcinogenesis (Varela-Rey et al., 
2012).  
Although there are different conclusions about light/moderate alcohol 
consumption being a protective factor or an increased risk factor of colorectal 
cancer, the studies all agreed that heavy alcohol consumption results in an 
increased risk of colorectal cancer in some or all subsites. The body mass index 
(BMI) is also considered to be a modifier of the impact of alcohol on colorectal 
cancer, with individuals whose BMI is higher than 30 having greater risk of 
colorectal cancer. Some studies also showed an increased risk, particularly in 
men, when the BMI was less than 22. Disagreement exists over the impact of 





There has been evidence that omega-3 oils play a role in reducing the risk 
of cancer and its progression. The benefits of fish oil have been ascribed to the 
omega-3 (n-3) polyunsaturated fatty acids (PUFAs) that it contains, such as 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (Ja Young Lee et 
al., 2017). A study of the effect of eicosapentaenoic acid monoacylglyceride 
(MAG-EPA) on colorectal cancer cells in vitro and in vivo using mouse subjects 
showed that MAG-EPA decreased cell proliferation and induced apoptosis of the 
cancer cells. It also reduced tumor growth by diminishing the activation of the 
epidermal growth factor receptor (EGFR), the vascular endothelial growth factor 
receptor (VEGFR), and Akt pathways to cause reduced VEGF expression in the 
tumors (Morin et al., 2017).   
Other studies have shown that polyunsaturated fatty acids can decrease 
cell proliferation in normal healthy people, which can result in tumor growth 
inhibition. The mechanism for the inhibition involves the cyclooxygenase 
enzyme which catalyzes arachidonic acids to prostaglandins. Polyunsaturated 
fatty acids, like docosahexaenoic acid, are primary components of fish oil and 
can inhibit cyclooxygenase-mediated metabolism (Ramos-Bueno et al., 2016). In 
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previous studies, supplementation with fish oil induced apoptosis and cell 
differentiation. Fish oil diminished cell proliferation, which is a key step in the 
process of cell development (Llor et al., 2003). Fish oil was also observed to 
specifically have an inhibitory effect on tumor cell growth (Ramos-Bueno et al., 
2016).  
Omega-3 polyunsaturated fatty acids have also been associated with 
improved outcomes for patients with colorectal cancer. Compared with the 
control group, those who supplemented with omega-3 had a reduced risk of 
postoperative infectious complication (15.58% vs 24.76%) (RR = 0.63, 95% CI 
[0.47, 0.86]). In a meta-analysis of six trials, hospital stay was reported with a 
significantly reduced time for those who consumed omega-3 compared with the 
control group (mean difference [MD] = -2.09 days) (95% CI [3.71, -0.48], p = 0.01) 
(Xie & Chang, 2016). 
In another study, patients receiving chemotherapy for colorectal cancer 
were given 2 g/day of fish oil while the control group did not receive fish oil or a 
placebo. At the end of the study, the time for tumor progression was observed to 
be significantly longer in the group that had supplemented with fish oil 
compared with the control group (593 days [±211.5] vs 330 days [± 135.1], p = 
0.04). A possible mechanism for the delay in tumor progression in colorectal 
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cancer was postulated by the researchers to be the ability of the fish oil to 
enhance the action of the chemotherapeutic drug (Camargo et al., 2016).  
In another systematic review, the effect of polyunsaturated fatty acids on 
inflammatory mediators was studied in colorectal cancer patients. PUFAs were 
seen to reduce the levels of interleukin-6 (standardized mean difference [SMD] = 
-2.34, 95% CI [-4.37, -0.31], p = 0.024) and increase the levels of albumin (SMD = 
0.31, 95% CI [0.06, 0.56], p = 0.014) in an overall analysis (Mocellin et al., 2016). 
Krill oil, which is another source of docosahexaenoic acid, inhibited cell 
proliferation and increased the formation of reactive oxygen species in three 
human cell lines and one mouse colorectal cell line (Jayathilake et al., 2019). The 
treatment of human colorectal cancer cells with eicosapentaenoic acid derived 
from fish oil resulted in treatment of the malignant tumor cells in a positive dose-
dependent manner. Cell proliferation with 200 μmol resulted in 30.3% compared 
with untreated control cells. Caspase-3 activity also increased as 
eicosapentaenoic acid concentration increased (Kalbkhani & Sam, 2018). 
In addition to the lifestyle factors discussed, disorders associated with 
chronic inflammation, such as ulcerative colitis, have been identified as 
increasing the risk of developing colon cancer. N-3 polyunsaturated fatty acids 
are said to by a protective factor because they have anti-inflammatory properties. 
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In a population study conducted in Italy, the levels of polyunsaturated fatty 
acids, including docosahexaenoic acid and eicosapentaenoic acid, were 
associated with a lower production of pro-inflammatory markers such as 
interleukin-6 and an increased number of anti-inflammatory markers. The 
reduction in inflammation translated into improved gas exchange and liver 
function. In addition, n-3 PUFAs were associated with a reduction in patient 
length of stay in the intensive care unit and in the hospital overall (Ja Young Lee 
et al., 2017).  
Similar to chronic inflammation, unresolved inflammation can lead to the 
development of colon cancer. Inflammation has also been described as the 
connection between obesity and colon cancer because obese patients with colon 
cancer have higher levels of serum C-reactive protein (CRP). This elevation in the 
levels of CRP showed a correlation with a poor prognosis for obese patients (Ja 
Young Lee et al., 2017).  
In multiple studies, dietary intake of n-3 PUFAs has been shown to 
improve the efficacy of chemotherapeutic agents. The combined treatment of 
colon cancer cells with the chemotherapeutic agent 5-fluorouracil and fish oil 
showed an increased growth inhibition compared with cells that were just 
exposed to 5-fluorouracil alone. The combination also increased the survival rate 
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of animals. DHA in particular was observed to potentiate the proapoptotic 
effects of 5-fluorouracil by downregulating antiapoptotic proteins and inducing 






There is evidence that physical activity reduces the risk of colon cancer 
overall, with some studies attributing 12%–14% of colon cancer cases to a lack of 
frequent physical activity (Slattery, 2004). Disagreement exists, however, on 
whether the reduction in risk is site-specific. A general review of the literature 
suggests that to reduce the risk of colon cancer, close to 4 hours of intense 
activity a week may be needed for optimal protection. Physical activity is 
thought to offer protective effects through biological mechanisms such as 
enhancing the immune system, decreasing levels of obesity, increasing gut 
motility, and enhancing free-radical scavenger systems (Slattery, 2004). 
 
Pre-Diagnosis Physical Activity 
 In a study by Schmid and Leitzmann (2014), survivors who had high 
levels of physical activity prior to diagnosis had a decreased risk of colorectal 
cancer mortality compared with those who had low levels of physical activity 
(RR = 0.75, 95% CI [0.62, 0.91]). A dose-response relationship was also observed 
with a 5, 10, or 15 metabolic equivalent task (MET)-hours/week increase in pre-
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diagnosis activity relating to a 7%, 14%, and 20% risk reduction for total 
mortality, respectively (Schmid & Leitzmann, 2014). 
 
Post-Diagnosis Physical Activity 
In a study conducted by van Zutphen and colleagues (2017) of 327 
incident colorectal patients, physical functioning was assessed after colorectal 
cancer surgery. Six months after diagnosis, 54% of patients had not recovered 
their physical functioning to preoperative levels. However, patients who 
increased their activity by at least an hour of exercise a week were 43% more 
likely to recover physical function compared with those whose activity levels did 
not change. Two groups of patients who increased their physical activity to 60-
240 min/week and ≥240 min/week both showed similar associations with 
recovery, having an adjusted prevalence ratio (PR) of 0.53 and 0.60, respectively. 
Those patients who had not recovered were also more likely to be smokers and 
patients with a BMI over 30 compared with those who had recovered (van 
Zutphen et al., 2017). 
A study by Schmid and Leitzmann (2014) reported that high physical 
activity post-diagnosis produced a strong risk reduction for colorectal cancer 
mortality (RR = 0.61, 95% CI [0.40, 0.92]). Each 5, 10, or 15 MET-hours/week 
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increase in post-diagnosis physical activity resulted in a 15%, 28%, and 38% 
lower risk of total mortality, respectively. This study also evaluated the results 
for breast cancer survivors and observed that survivors of breast cancer and 
colon cancer who increased their physical activity level had a decreased risk of 
total mortality (RR = 0.61, 95% CI [0.46, 0.80]) and cancer mortality (RR = 0.71, 
95% CI [0.45, 1.12]). On the other hand, individuals who decreased their physical 
activity level during the pre- to post-diagnosis period had a nonsignificant 
increase in risk of total mortality (RR = 1.72, 95% CI [0.76, 3.87]) and cancer 
mortality (RR = 1.28, 95% CI [0.87, 1.90]) when compared with those who did not 
change their physical activity level (Schmid & Leitzmann, 2014). 
Another meta-analysis evaluating multiple patients showed that physical 
activity was negatively associated with overall mortality (RR = 0.81, 95% CI [0.72, 
0.91]) and colorectal cancer mortality (RR = 0.79, 95% CI [0.71, 0.89]) prior to 
diagnosis (Wu et al., 2016). Physical activity after diagnosis also had a similar 
inverse association for total mortality (RR = 0.71, 95% CI [0.63, 0.81]) and cancer-
specific mortality (RR = 0.77, 95% CI [0.63, 0.94]) (Wu et al., 2016).  
When the association between physical activity and colorectal cancer was 
stratified by tumor markers in a study by Hardikar and coworkers (2015), the 
inverse relationship was most evident in MSI-high tumors (HR = 0.46, 95% CI 
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[0.17, 1.25]) and less pronounced in BRAF mutated colorectal cancers (HR = 0.76, 




BODY MASS INDEX 
 
Obesity has been established as being a risk factor for colorectal cancer 
and colorectal cancer mortality. In a colon cancer control study that had 46,551 
participants, those with a higher body mass index (BMI) had an increased risk of 
cancer mortality (HR = 1.03, 95% CI [1.00, 1.05]) (Shaukat et al., 2017).  
In the Framingham Study, it was observed that a BMI ≥30 resulted in a 
50% increased risk (RR = 1.5, 95% CI [0.92, 2.5]) of colon cancer among 
individuals between 30 and 54 years old and 2.4 times the risk (RR = 2.4, 95% CI 
[1.5, 3.9]) among adults between 55 and 79 years old (Moore et al., 2004). Overall, 
for the participants who were 30–79 years old at the time of baseline BMI, there 
was a 40% increased risk (RR = 1.4, 95% CI [1.0, 1.9]) of colon cancer for those 
with a BMI between 25 and 30 (classified as overweight) and a 60% increased risk 
(RR = 1.6, 95% CI [1.0, 2.5]) for those with a BMI above 30 (classified as obese) 
when they were compared with those with a normal BMI. Having a higher BMI 
was also observed to have more of an association with colorectal cancer for men 
than for women. In addition, older obese subjects in this group had 3 times 
increased risk of proximal cancer (RR = 2.9, 95% CI [1.6, 5.2]), whereas middle-
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aged obese subjects had a 60% increased risk of proximal colon cancer (Moore et 
al., 2004). 
A systematic review of 18 observational studies by Doleman and 
associates (2016) found that obese patients had an increased risk of all-cause 
mortality (RR = 1.14, 95% CI [1.07, 1.21]) and cancer-specific mortality (RR = 1.14, 
95 % CI [1.05, 1.24]). Underweight patients also had an increased risk of all-cause 
mortality (RR = 1.43, 95 % CI [1.26, 1.62]) and cancer-specific mortality (RR = 1.50, 
95 % CI [1.20, 1.87]) (Doleman et al., 2016). 
In an age-specific BMI analysis, subjects who were classified as 
overweight/obese at the age of 20 had a higher CRC risk than those who were 
never overweight/obese (HR = 1.28, 95% CI [1.11, 1.48]) (Zheng et al., 2018). A 
weight gain greater than or equal to 15 kg between the ages of 20 and 50 resulted 
in an increase in CRC risk (HR = 1.34, 95% CI [1.18, 1.52]), even with adjustment 
for initial weight. Furthermore, changes in BMI between the onset of adulthood 
and the baseline measurement for the study indicated increased risk. Subjects 
who initially had a normal BMI but were obese at baseline had an increased risk 
of 1.18 (95% CI [1.03, 1.35]). Subjects who were overweight at the onset of 
adulthood and obese at baseline also showed an increased risk compared with 
those who had a normal BMI throughout adulthood (HR = 1.27, 95% CI [0.99, 
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1.64]). When a stratified analysis was conducted for characteristics including 
cigarette smoking and family history of CRC, a strong association was not 
observed between these factors and the influence of BMI on CRC risk (Zheng et 
al., 2018). 
In a systematic review of 56 studies that evaluated the association between 
body mass index and colorectal cancer, Ning and coworkers (2010) found that 
BMI values of <23, 23–24.9, 25–27.4, 26.5–29.9, and ≥30.0 were associated with 
increased risks of 1.14 (95% CI [1.06, 1.23]), 1.19 (95% CI [1.13, 1.25]), 1.24 (95% CI 
[1.15, 1.35]), and 1.41 (95% CI [1.30, 1.53]), respectively. For every increment of 5 
in BMI, there was an associated increased risk of 26% for colon cancer when 
adjusted for physical activity. This association appeared to be stronger for colon 
cancer than for rectal cancer (Ning et al., 2010).  
Information was collected on a cancer prevention study cohort of 2303 
participants over a 16-year follow-up period (Campbell et al., 2012). Analysis of 
the data showed that those with a pre-diagnosis obese BMI had a higher risk of 
mortality from all causes relative to those with a normal BMI (RR = 1.30, 95% CI 
[1.06, 1.58]) and colorectal cancer (RR = 1.35, 95% CI [1.01, 1.80]). Post-diagnosis 
BMI was not associated with all-cause or colorectal cancer mortality. When the 
participants were stratified by stage at diagnosis, those with obese BMI had a 
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worse prognosis for localized disease compared with those with normal BMI 
(Campbell et al., 2011).  
In another multivariate study focused on apparently healthy women over 
the age of 45, women with a BMI of 27–29.9 and a BMI ≥30 had relative risks of 
1.72 (95% CI [1.12, 2.66]) and 1.67 (95% CI[1.08, 2.59]), respectively, when 







A case control study of 579 colorectal cancer patients and their matched 
controls was stratified into quintiles for dietary fiber intake (Dahm et al., 2010). 
Those in the highest quintile of dietary fiber intake had 25% lower risk of 
developing colorectal cancer compared with those in the lowest quintile of 
dietary fiber intake (OR = 0.75, 95% CI [0.55, 1.02]). This association was present 
even when the analyses were adjusted for patient BMI and alcohol consumption. 
For incident colon cancer, when the same analyses were run, a quintile increase 
in fiber intake also resulted in a decreased risk of colon cancer (OR = 0.90, 95% CI 
[0.81, 0.99], p = .029) (Dahm et al., 2010). 
Kunzmann and colleagues (2015) proposed a study to evaluate the 
relationship between dietary fiber intake and the risk of incident and recurrent 
colorectal adenoma and incident colorectal cancer. They observed that an 
elevated intake of total dietary fiber resulted in reduced ratio of incident distal 
colorectal adenoma in the highest tertile when compared with the lowest tertile 
(OR = 0.76, 95% CI [0.63, 0.91]). A statistically significant association was not 
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observed for recurrent adenoma, but protective associations were most 
attributed to dietary fiber from cereals and fruit (Kunzmann et al., 2015). 
 
Folate Supplementation  
Folate supplementation has often been considered a protective factor for 
colorectal cancer risk, but there is some disagreement in the findings about 
whether it has a significant effect on colorectal cancer risk. A critical review of 
the literature from January 2000 to September 2016 by Moazzen and coworkers 
(2018) found that folic acid supplement intake did not show an effect on 
colorectal risk in randomized control trials (RR = 1.07, 95% CI [0.86, 1.43]) and 
cohort studies (RR = 0.96, 95% CI [0.76, 1.21]). With an increase in total folate 
intake, however, a reduced risk was observed in cohort studies (RR = 0.71, 95% 
CI [0.59, 0.86]) and case control studies (RR = 0.77, 95% CI [0.62, 0.95]) (Moazzen 






The purpose of this study was to review the available literature on 
lifestyle factors that impact the prevalence, presentation, and mortality of 
colorectal cancer. These factors were tobacco smoking, alcohol, fish oil, physical 
activity, body mass index, and diet. 
Cigarette smoking was one of the more established risk factors and was 
observed to particularly increase the risk of cancer that was CIMP-positive and 
BRAF mutant. A dose-response relationship existed between smoking and 
colorectal cancer risk, and variables like pack-year and length of smoking had an 
impact on the risk. Smoking cessation was observed to mitigate some of the 
acquired risk.  
Alcohol consumption was another risk factor, and heavy drinking was 
found to increase levels of colorectal cancer mortality. The effects of alcohol 
consumption on colorectal risk were likely modulated by other factors such as 
family history of colorectal risk and body mass index. There was disagreement 




The omega-3 polyunsaturated fatty acids in fish oil were observed to be a 
protective factor by inhibiting tumor cell growth and improving patient 
outcomes after treatment. When used in conjunction with treatment, these fatty 
acids were observed to increase the timeline for tumor progression and to reduce 
the length of hospital stay. 
Physical activity, especially prior to diagnosis, was a factor that improved 
patient outcomes by decreasing the risk of colorectal cancer mortality. An 
increase in physical activity levels post-diagnosis also improved patient 
outcomes.  
A BMI classified as obese increased the risk of colon cancer compared 
with a normal BMI, particularly in the proximal region of the colon. 
Underweight patients also had an increased risk of cancer-specific mortality. 
Diet was the final factor playing a role in colorectal risk. High dietary fiber 
and increased total folate intake contributed to reducing the risk of colon cancer. 
The limitations of this literature review include the diversity in sample 
sizes of the studies that were compared for the various lifestyle factors and the 
variability in timing of these studies. However, the results of this review can 
inform directions for further research on lifestyle factors associated with 
colorectal cancer. Future studies could focus on those lifestyle factors that were 
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observed to have a positive impact on colorectal cancer, such as omega-3 
polyunsaturated fatty acids in fish oil, and their use as a way to improve the 
outcomes of colorectal cancer patients. These future studies could evaluate what 
modes of administration and dosage of the medication have the most impact on 
the disease. Future studies could also determine the most effective time for 
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